Protein molecules play a critical role in the development of biological drugs such as monoclonal antibody medications, biovaccines, and diagnostic kits. Accurate determination of protein sequences is crucial in the research and development of commercial monoclonal antibodies, vaccines, and diagnostic kits. Peptide Pioneer, leveraging the high-resolution mass spectrometer Obitrap Fusion Lumos, in conjunction with extensive bioinformatics analysis experience, has established a new generation platform for protein de novo sequencing and mutation analysis, enablingmonoclonal antibody primary structure sequence,protein sequence and mutationto be analyzed quickly and accurately.
de novo sequencing
Advantages of De Novo Sequencing Service
1. Utilizes high-resolution mass spectrometry instrument Obitrap Fusion Lumos
2. High sample coverage: up to 100%
3. High initial amino acid accuracy: up to 95%
4. Low sample requirement: only 100ug needed for detection
Peptide Pioneer offers the following de novo sequencing services:
